<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>THEMISMED</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">THEMISMED</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="themis-medicare-limited" class="section level1">
<h1>Themis Medicare Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.THEMISMED.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.THEMISMED.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.THEMISMED.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.THEMISMED.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.THEMISMED.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.THEMISMED.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.THEMISMED.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.THEMISMED.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.THEMISMED.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p>Based on the comprehensive set of documents provided for <strong>Themis Medicare Limited (THEMISMED)</strong> ‚Äî including <strong>unaudited financial results</strong>, <strong>corporate updates</strong>, <strong>AGM voting results</strong>, <strong>auditor review reports</strong>, and <strong>material corporate actions</strong> ‚Äî here is a structured analysis of the <strong>headwinds</strong>, <strong>tailwinds</strong>, <strong>growth prospects</strong>, and <strong>key risks</strong> as of <strong>November 2025</strong>.</p>
<hr />
<div id="company-overview" class="section level6">
<h6>üîç <strong>Company Overview</strong></h6>
<ul>
<li><strong>Sector</strong>: Pharmaceuticals (Domestic Formulations)</li>
<li><strong>Headquarters</strong>: Mumbai, India</li>
<li><strong>Listed on</strong>: BSE (Scrip: 530199) &amp; NSE (Symbol: THEMISMED); ISIN: INE083B01024</li>
<li><strong>Core Business</strong>: Pharmaceuticals (single segment under Ind AS 108)</li>
<li><strong>Key Operations</strong>: Manufacturing and marketing of pharmaceutical formulations in India</li>
</ul>
<hr />
</div>
<div id="financial-highlights-unaudited-q2-fy26-h1-fy26-ended-30-sep-2025" class="section level6">
<h6>üìà Financial Highlights (Unaudited Q2 FY26 / H1 FY26 ended 30-Sep-2025)</h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2 FY26 (3 months ended 30-Sep-25)</th>
<th>YoY Change</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Standalone Revenue (Operations)</strong></td>
<td>‚Çπ7,799.41 Cr</td>
<td>‚ñº -33.4%</td>
</tr>
<tr class="even">
<td><strong>Net Total Income</strong></td>
<td>‚Çπ8,123.05 Cr</td>
<td>‚ñº -31.4%</td>
</tr>
<tr class="odd">
<td><strong>Profit Before Tax (PBT)</strong></td>
<td>(‚Çπ519.06) Cr (Loss)</td>
<td>‚ñº -138.8% (from +‚Çπ1,337 Cr)</td>
</tr>
<tr class="even">
<td><strong>Net Loss</strong></td>
<td>(‚Çπ535.55) Cr</td>
<td>‚ñº -154% (from +‚Çπ987 Cr profit)</td>
</tr>
<tr class="odd">
<td><strong>EPS (Basic - Standalone)</strong></td>
<td>‚Çπ(0.58)</td>
<td>‚ñº from ‚Çπ1.08</td>
</tr>
<tr class="even">
<td><strong>Consolidated Net Loss</strong></td>
<td>(‚Çπ361.56) Cr</td>
<td>‚ñº from +‚Çπ1,429 Cr profit</td>
</tr>
<tr class="odd">
<td><strong>Cash &amp; Equivalents (Standalone)</strong></td>
<td>‚Çπ804.35 Cr</td>
<td>‚ñº from ‚Çπ646.64 Cr (prev period)</td>
</tr>
<tr class="even">
<td><strong>Liabilities (Total, Standalone)</strong></td>
<td>‚Çπ48,802 Cr</td>
<td>Slight increase</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Note</strong>: All figures in <strong>INR Lakhs (0.01 million)</strong> = e.g., ‚Çπ7,799.41 Cr = ‚Çπ77,994.1 million</p>
</blockquote>
<hr />
</div>
<div id="headwinds-negative-factors" class="section level3">
<h3>üå¨Ô∏è <strong>Headwinds (Negative Factors)</strong></h3>
<div id="steep-decline-in-revenue-profitability" class="section level9">
<p class="heading">1. <strong>Steep Decline in Revenue &amp; Profitability</strong></p>
<ul>
<li><strong>Q2 revenue</strong> dropped <strong>33% YoY</strong> to ‚Çπ7,800 Cr (from ‚Çπ11,700 Cr).</li>
<li><strong>Half-year revenue</strong> down to ‚Çπ17,557 Cr from ‚Çπ24,000 Cr ‚Äî a <strong>26.8% decline</strong>.</li>
<li><strong>Net loss of ‚Çπ535.55 Cr</strong> (vs.¬†‚Çπ987 Cr profit YoY) ‚Äî a <strong>swing of over ‚Çπ1,500 Cr</strong>.</li>
<li>Likely due to <strong>competitive pricing pressure</strong>, <strong>market share erosion</strong>, or <strong>supply chain disruptions</strong>.</li>
</ul>
</div>
<div id="unfavorable-demand-or-market-dynamics" class="section level9">
<p class="heading">2. <strong>Unfavorable Demand or Market Dynamics</strong></p>
<ul>
<li>The document indicates that <strong>management now aims to focus on core domestic formulations</strong> following the <strong>aborted merger</strong> with <em>Gujarat Themis Biosyn Ltd (GTBL)</em>, suggesting the earlier strategy to consolidate was an attempt to counter softening conditions.</li>
<li>Revenue collapse cannot be fully explained by one-off items ‚Äî <strong>indicative of deeper structural issues</strong> in commercial execution.</li>
</ul>
</div>
<div id="poor-operating-cash-flow" class="section level9">
<p class="heading">3. <strong>Poor Operating Cash Flow</strong></p>
<ul>
<li><strong>Net cash outflow from operations</strong>: ‚Çπ148.40 Cr (after tax outflow of ‚Çπ21.73 Cr), despite non-cash expenses.</li>
<li>This indicates <strong>working capital stress</strong>, <strong>rising receivables</strong>, or <strong>inventory build-up</strong>.
<ul>
<li>Trade receivables up to ‚Çπ17,342 Cr from ‚Çπ17,745 Cr?</li>
<li>Inventory down to ‚Çπ7,644 Cr from ‚Çπ8,431 Cr ‚Äî positive sign, but may reflect low production.</li>
</ul></li>
</ul>
</div>
<div id="high-interest-costs" class="section level9">
<p class="heading">4. <strong>High Interest Costs</strong></p>
<ul>
<li><strong>Finance costs</strong>: ‚Çπ276.49 Cr in Q2 ‚Äî over <strong>3x the finance cost of Q2 FY25</strong> (‚Çπ244 Cr)? Wait ‚Äî actually <strong>only slight increase</strong> from ‚Çπ244 Cr, but elevated vs.¬†revenue base.</li>
<li>Interest coverage is under strain due to <strong>falling earnings</strong>.</li>
</ul>
</div>
<div id="exceptional-write-offs-coming-soon" class="section level9">
<p class="heading">5. <strong>Exceptional Write-offs (Coming Soon)</strong></p>
<ul>
<li>Recognition of <strong>‚Çπ128.63 Cr loss</strong> (Receivables &amp; Advances) and <strong>‚Çπ0.76 Cr investment loss</strong> from <strong>strike-off of UK subsidiary <em>Carpo Medicals Limited</em></strong>.</li>
<li>Though not yet charged (awaiting RBI/FEMA approvals), these <strong>could hit P&amp;L in upcoming quarters</strong>, worsening net loss.</li>
</ul>
<hr />
</div>
</div>
<div id="tailwinds-positive-factors-supports" class="section level3">
<h3>üå™Ô∏è Tailwinds (Positive Factors / Supports)</h3>
<div id="strong-cash-reserves-standalone" class="section level9">
<p class="heading">1. <strong>Strong Cash Reserves (Standalone)</strong></p>
<ul>
<li><strong>Cash &amp; Cash Equivalents</strong>: ‚Çπ804.35 Cr (up from ‚Çπ646.64 Cr MoM).</li>
<li>Provides <strong>liquidity buffer</strong> to weather near-term losses.</li>
</ul>
</div>
<div id="debt-management-via-financing" class="section level9">
<p class="heading">2. <strong>Debt Management via Financing</strong></p>
<ul>
<li><strong>Net cash inflow from financing</strong>: ‚Çπ374.05 Cr ‚Üí primarily due to <strong>fresh borrowings</strong> (+‚Çπ1,358 Cr short-term).</li>
<li>Signals <strong>access to credit markets</strong> despite weak earnings.</li>
</ul>
</div>
<div id="focus-on-core-domestic-formulations" class="section level9">
<p class="heading">3. <strong>Focus on Core Domestic Formulations</strong></p>
<ul>
<li>After <strong>abandoning the GTBL merger</strong>, management plans to <strong>return to core business</strong>.</li>
<li>Potentially simplifying operations, reducing complexity, and refocusing on <strong>profitable domestic portfolios</strong>.</li>
</ul>
</div>
<div id="board-stability-shareholder-approval" class="section level9">
<p class="heading">4. <strong>Board Stability &amp; Shareholder Approval</strong></p>
<ul>
<li><strong>55th AGM (Sept 12, 2025)</strong> passed all 7 resolutions with overwhelming shareholder support:
<ul>
<li>Ratification of audited financials, director reappointment (Adam Demeter), <strong>dividend declaration</strong>, appointment of Independent Director (Neha Thakore).</li>
</ul></li>
<li><strong>Over 99.9% in favor</strong> across key resolutions ‚Äî shows <strong>strong promoter and public confidence</strong>.</li>
</ul>
</div>
<div id="reassessment-of-strategic-direction" class="section level9">
<p class="heading">5. <strong>Reassessment of Strategic Direction</strong></p>
<ul>
<li>Withdrawing from a potentially <strong>dilutive or complex merger</strong>, the company avoids integration risks and can pursue <strong>organic growth</strong> and <strong>productivity improvements</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects" class="section level3">
<h3>üíº Growth Prospects</h3>
<div id="domestic-market-focus" class="section level9">
<p class="heading">1. <strong>Domestic Market Focus</strong></p>
<ul>
<li>India‚Äôs <strong>pharmaceutical formulations market</strong> continues to grow at ~8‚Äì10% CAGR, driven by:
<ul>
<li>Increasing healthcare penetration</li>
<li>Government health schemes</li>
<li>Chronic disease burden</li>
</ul></li>
<li>Opportunity to <strong>regain market share</strong> in anti-diabetics, antibiotics, or generics.</li>
</ul>
</div>
<div id="efficiency-optimization" class="section level9">
<p class="heading">2. <strong>Efficiency Optimization</strong></p>
<ul>
<li><strong>Consolidated EBITDA margin</strong> hovered near break-even (PBT ~‚Äì‚Çπ345 Cr on ‚Çπ8,123 Cr revenue).</li>
<li>With <strong>revenue stabilizing</strong>, even modest <strong>cost rationalization</strong> can lead to <strong>return to profitability</strong>.</li>
</ul>
</div>
<div id="investment-in-associates-may-pay-off" class="section level9">
<p class="heading">3. <strong>Investment in Associates May Pay Off</strong></p>
<ul>
<li><strong>Equity-income</strong> from associates: ‚Çπ173.99 Cr in Q2.
<ul>
<li><strong>Joint Ventures/Associates</strong>:
<ul>
<li><em>Gujarat Themis Biosyn</em> (though merger off)</li>
<li><em>Richter Themis Medicare (India)</em> ‚Äì likely a high-value JV</li>
<li><em>Long Island Nutritionals</em></li>
</ul></li>
</ul></li>
<li>These may yield <strong>future upside</strong> in margins or new product launches.</li>
</ul>
</div>
<div id="potential-divestments-or-rationalization" class="section level9">
<p class="heading">4. <strong>Potential Divestments or Rationalization</strong></p>
<ul>
<li>Closure of UK subsidiary indicates <strong>global footprint review</strong> ‚Äî future <strong>non-core asset exits</strong> may unlock capital.</li>
</ul>
<hr />
</div>
</div>
<div id="key-risks" class="section level3">
<h3>‚ö†Ô∏è Key Risks</h3>
<div id="unsustainable-loss-trajectory" class="section level9">
<p class="heading">1. <strong>Unsustainable Loss Trajectory</strong></p>
<ul>
<li>Two consecutive quarters of losses, with <strong>net loss of ‚Çπ2,072.92 Cr in H1 FY26</strong>.</li>
<li>If losses continue, <strong>equity erosion</strong> could trigger <strong>debt covenants breach</strong> or <strong>rating downgrade</strong>.</li>
</ul>
</div>
<div id="reliance-on-debt-for-liquidity" class="section level9">
<p class="heading">2. <strong>Reliance on Debt for Liquidity</strong></p>
<ul>
<li>Current reliance on <strong>short-term borrowings</strong> (‚Çπ7,795 Cr current borrowings) raises refinancing risk.</li>
<li><strong>Debt-to-equity</strong> (standalone): Liabilities ~‚Çπ48,800 Cr vs.¬†Equity ‚Çπ29,480 Cr ‚Üí <strong>~1.65x</strong> ‚Äî elevated.</li>
</ul>
</div>
<div id="regulatory-compliance-risks" class="section level9">
<p class="heading">3. <strong>Regulatory &amp; Compliance Risks</strong></p>
<ul>
<li>Awaiting <strong>RBI/FEMA approval</strong> to write off foreign subsidiary.</li>
<li>Delays could lead to <strong>prolonged impairment</strong>, <strong>reputational risk</strong>, or compliance penalties.</li>
</ul>
</div>
<div id="investor-sentiment-stock-market-reaction" class="section level9">
<p class="heading">4. <strong>Investor Sentiment &amp; Stock Market Reaction</strong></p>
<ul>
<li>Market may react negatively to:
<ul>
<li><strong>Revenue collapse</strong></li>
<li><strong>Large losses</strong></li>
<li><strong>Abandonment of strategic merger</strong></li>
</ul></li>
<li>Stock may face <strong>valuation pressure</strong> until turnaround demonstrated.</li>
</ul>
</div>
<div id="operational-inefficiency" class="section level9">
<p class="heading">5. <strong>Operational Inefficiency</strong></p>
<ul>
<li><strong>Other expenses</strong>: ‚Çπ3,200 Cr in Q2 ‚Äî higher than revenue growth, possibly indicating underutilized capacity or bloated SG&amp;A.</li>
<li>Raw material costs are <strong>down</strong> (Cost of Materials: ‚Çπ1,610 Cr vs.¬†‚Çπ2,105 Cr), but revenue drop offsets savings.</li>
</ul>
<hr />
</div>
</div>
<div id="summary-themis-medicare-limited-themismed-investment-snapshot-nov-2025" class="section level3">
<h3>üìä Summary: THEMIS MEDICARE LIMITED (THEMISMED) ‚Äì Investment Snapshot (Nov 2025)</h3>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th>Category</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Headwinds</strong></td>
<td>Severe revenue contraction (~33% YoY), operating loss, cash flow strain, UK subsidiary wind-down, rising interest burden</td>
</tr>
<tr class="even">
<td><strong>Tailwinds</strong></td>
<td>Strong cash balance, access to debt financing, shareholder confidence, strategic refocus on core</td>
</tr>
<tr class="odd">
<td><strong>Growth Prospects</strong></td>
<td>Return to profitability via cost control; potential from JVs; rebuilding domestic formulations business</td>
</tr>
<tr class="even">
<td><strong>Key Risks</strong></td>
<td>Sustainability of negative earnings, high leverage, reliance on RBI approvals, weak investor sentiment, competitive pressures</td>
</tr>
<tr class="odd">
<td><strong>Verdict</strong></td>
<td><strong>High-risk turnaround candidate</strong> ‚Äì currently in a trough. If management stabilizes operations and controls costs, <strong>long-term upside possible</strong>. Not suitable for conservative investors.</td>
</tr>
</tbody>
</table>
<hr />
<div id="conclusion" class="section level6">
<h6>üîö Conclusion</h6>
<p><strong>Themis Medicare Limited</strong> is undergoing a <strong>challenging transition phase</strong>, marked by a <strong>sharp revenue decline</strong>, <strong>losses</strong>, and <strong>abrupt reversal of a strategic merger</strong>. While <strong>financial stability is maintained through strong cash reserves and continued market access</strong>, the <strong>core business appears under pressure</strong>.</p>
<p>However, the <strong>pivot back to domestic formulations</strong>, <strong>successful AGM outcomes</strong>, and <strong>strong affiliate performance</strong> suggest that <strong>management is attempting course correction</strong>.</p>
<p><strong>For investors</strong>: This is a <strong>speculative, turnaround opportunity</strong>. <strong>Monitor next quarter closely</strong> for: - Signs of <strong>revenue stabilization</strong> - <strong>Cost containment</strong> - <strong>Resolution of foreign subsidiary write-off</strong> - <strong>Positive operating cash flow</strong></p>
<p>Until then, exercise caution. The company‚Äôs <strong>future depends on execution</strong> ‚Äî not strategy.</p>
<hr />
<blockquote>
<p><strong>Key Watchlist Indicators</strong>: - Q3 FY26 revenue trend (Dec 2025) - PBT turn positive - Cash flow from operations turns positive - RBI approval received for UK subsidiary wind-down - SG&amp;A expense rationalization</p>
</blockquote>
<hr />
<p><strong>Sources</strong>:<br />
- Unaudited Financial Results (13-Nov-2025)<br />
- Board Meeting Outcome Letter<br />
- Auditor Review Reports (Krishaan &amp; Co.)<br />
- Scrutinizer‚Äôs Report (55th AGM, 12-Sep-2025)<br />
- Notes &amp; Disclosures included in filings</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
